Medinotec Inc

Medinotec Inc exhibits a strong liquidity position, with a current ratio of 4.27, indicating the company can cover its short-term liabilities more than four times over. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its operating cash flow of $877,830 and free cash flow of $2,233,320. The debt-to-equity ratio of 0.22 reflects a conservative capital structure, with long-term debt of $940,280 compared to total equity of $4,270,830. In terms of profitability, Medinotec Inc generates a return on equity (ROE) of 50.56% and a return on assets (ROA) of 31.72%, both of which are well above the industry median for medical equipment and supplies firms. The company's operating income of $3,191,500 and net income of $2,159,470 suggest strong operational efficiency and margin control. Gross profit of $4,860,790 on revenue of $9,113,610 indicates a healthy gross margin, which is a key performance indicator for the industry. The company's revenue is split between two segments: Sales Outside the United States and Domestic Sales. The Domestic Sales segment focuses on the proprietary Trachealator product within the United States, while the Sales Outside the United States segment includes both internally developed and third-party products. Geographically, Medinotec Inc has a direct sales force in South Africa and the United States, with the remainder of its sales distributed through a network of international distributors. This distribution model suggests a moderate level of geographic diversification, with a concentration in the U.S. and South Africa. Looking at growth, Medinotec Inc has demonstrated strong financial performance in the current fiscal year, with a net income of $2,159,470 and free cash flow of $2,233,320. The company's outlook for the next fiscal year is positive, with expected growth in both revenue and profitability. The company's operating cash flow of $877,830 and free cash flow of $2,233,320 support its ability to fund operations and invest in future growth. Risk factors for Medinotec Inc include a medium liquidity risk, as the company has a net cash position that is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the near term. The company's conservative capital structure and strong cash flow generation reduce the likelihood of near-term dilution. The risk assessment also highlights the importance of maintaining strong cash flow to support operations and reduce liquidity risk. Recent events and filings for Medinotec Inc include the latest financial snapshot, which provides a comprehensive view of the company's financial health. The company's financial performance and risk profile are consistent with its industry peers, and there are no significant new risks or events that have been disclosed in the latest filings. The company's focus on tracheal non-occlusive airway dilatation technology and its strong financial position suggest a stable and growing business.